The extent of mediastinal lymph node dissection correlates with survival of small cell lung cancer patients after resection: a propensity score-matched cohort study analysis.
Small cell lung cancer (SCLC)
lymphadenectomy
prognosis
surgical resection
survival
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
06
05
2022
accepted:
18
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
ppublish
Résumé
Evidence on the importance of lymph node (LN) dissection during resection for small cell lung cancer (SCLC) is scarce. This study sought to investigate the clinical impact of the extent of lymphadenectomy on the survival of patients with SCLC. Patients who underwent resection for primary SCLC between 2000 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) cancer registry. The patients were stratified based on the number of LNs dissected (0, 1-3, 4-11, and ≥12) via an X-Tile software analysis, and lung cancer-specific survival (LCSS) and overall survival (OS) were compared between these stratified groups using Kaplan-Meier curves. A propensity score-matched analysis and a Cox regression model were used to adjust for potential confounders. A total of 1,883 patients with SCLC met our criteria and were enrolled in the study. The LCSS and OS analyses revealed that patients who underwent LN dissection during surgery had longer survival times significantly than patients who did not. Similarly, patients who underwent more extensive LN dissection (≥4 LNs) had longer survival times than those who underwent less extensive LN dissection (1-3 LNs). However, no significant increase in survival time was found for patients who underwent the dissection of ≥12 LNs compared to those who underwent the dissection of 4-11 LNs. These results were confirmed in our propensity-matched and Cox regression analyses. Our study revealed that patient survival after surgical resection for SCLC is associated with the number of dissected LNs, and the number of LNs for dissection ranges from 4 to 11 achieve the best survival outcome.
Sections du résumé
Background
UNASSIGNED
Evidence on the importance of lymph node (LN) dissection during resection for small cell lung cancer (SCLC) is scarce. This study sought to investigate the clinical impact of the extent of lymphadenectomy on the survival of patients with SCLC.
Methods
UNASSIGNED
Patients who underwent resection for primary SCLC between 2000 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) cancer registry. The patients were stratified based on the number of LNs dissected (0, 1-3, 4-11, and ≥12) via an X-Tile software analysis, and lung cancer-specific survival (LCSS) and overall survival (OS) were compared between these stratified groups using Kaplan-Meier curves. A propensity score-matched analysis and a Cox regression model were used to adjust for potential confounders.
Results
UNASSIGNED
A total of 1,883 patients with SCLC met our criteria and were enrolled in the study. The LCSS and OS analyses revealed that patients who underwent LN dissection during surgery had longer survival times significantly than patients who did not. Similarly, patients who underwent more extensive LN dissection (≥4 LNs) had longer survival times than those who underwent less extensive LN dissection (1-3 LNs). However, no significant increase in survival time was found for patients who underwent the dissection of ≥12 LNs compared to those who underwent the dissection of 4-11 LNs. These results were confirmed in our propensity-matched and Cox regression analyses.
Conclusions
UNASSIGNED
Our study revealed that patient survival after surgical resection for SCLC is associated with the number of dissected LNs, and the number of LNs for dissection ranges from 4 to 11 achieve the best survival outcome.
Identifiants
pubmed: 35958338
doi: 10.21037/tlcr-22-489
pii: tlcr-11-07-1453
pmc: PMC9359967
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1453-1467Informations de copyright
2022 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-489/coif). The authors have no conflicts of interest to declare.
Références
J Thorac Oncol. 2008 Aug;3(8):880-6
pubmed: 18670306
Chest. 1994 Dec;106(6 Suppl):320S-323S
pubmed: 7988254
Eur J Cardiothorac Surg. 2005 Apr;27(4):680-5
pubmed: 15784374
Lancet. 2011 Nov 12;378(9804):1741-55
pubmed: 21565397
J Clin Oncol. 2009 Oct 10;27(29):4881-4
pubmed: 19738112
N Engl J Med. 2013 Sep 5;369(10):920-31
pubmed: 24004119
J Thorac Cardiovasc Surg. 2018 Aug;156(2):796-805.e4
pubmed: 29716729
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Thorac Surg. 2004 Mar;77(3):1028-32
pubmed: 14992920
J Thorac Oncol. 2015 Jul;10(7):990-1003
pubmed: 26134221
Ann Thorac Surg. 2017 Jun;103(6):1767-1772
pubmed: 28385378
Lung Cancer. 2015 Apr;88(1):52-6
pubmed: 25662387
J Clin Oncol. 2003 Mar 15;21(6):1029-34
pubmed: 12637467
Curr Probl Cancer. 2012 Jul-Aug;36(4):216-24
pubmed: 22481009
Chest. 2005 Sep;128(3):1545-50
pubmed: 16162756
J Thorac Cardiovasc Surg. 2016 Jun;151(6):1484-7
pubmed: 27207121
J Clin Oncol. 2015 Dec 1;33(34):4106-11
pubmed: 26351333
Chin Clin Oncol. 2020 Aug;9(4):59
pubmed: 32036674
Ann Thorac Surg. 2017 May;103(5):1647-1653
pubmed: 28267977
Lung Cancer. 2017 Jan;103:75-81
pubmed: 28024700
Ann Thorac Surg. 2012 Sep;94(3):889-93
pubmed: 22429675
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
Thorax. 2014 Mar;69(3):269-73
pubmed: 24172710
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
Cancer. 2009 Feb 15;115(4):851-8
pubmed: 19140203
Ann Thorac Surg. 2014 Feb;97(2):385-93
pubmed: 24266949
Ann Thorac Surg. 2017 Dec;104(6):1872-1880
pubmed: 29106886
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Interact Cardiovasc Thorac Surg. 2019 Jan 1;28(1):41-44
pubmed: 30053292
Lancet. 1973 Jul 14;2(7820):63-5
pubmed: 4123619
Lung Cancer. 2015 Dec;90(3):548-53
pubmed: 26604032
Chest. 2012 Dec;142(6):1380-1382
pubmed: 23208333
Ann Surg. 2018 Dec;268(6):1105-1112
pubmed: 28475559
J Clin Oncol. 2017 Apr 10;35(11):1162-1170
pubmed: 28029318